Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply.

Authors	Jonathan I Silverberg, Emma Guttman-Yassky, Renata Gontijo Lima
Journal	The New England journal of medicine (N Engl J Med) Vol. 388 Issue 24 Pg. 2299-2300 (Jun 15 2023) ISSN: 1533-4406 [Electronic] United States
PMID	37314719 (Publication Type: Letter, Comment)
Chemical References	lebrikizumab Antibodies, Monoclonal
Topics	Humans Dermatitis, Atopic (drug therapy) Antibodies, Monoclonal (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!